TCGA-73-7499-01A-11R-2187-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- OXIDATIVE_PHOSPHORYLATION+0.470
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.420
- E2F_TARGETS+0.330
- FATTY_ACID_METABOLISM+0.290
- PEROXISOME+0.260
- BILE_ACID_METABOLISM+0.210
- COMPLEMENT+0.200
- DNA_REPAIR+0.170
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.500
- TGF_BETA_SIGNALING-0.500
- WNT_BETA_CATENIN_SIGNALING-0.490
- MITOTIC_SPINDLE-0.460
- UV_RESPONSE_DN-0.390
- HYPOXIA-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- APICAL_JUNCTION-0.310
- TNFA_SIGNALING_VIA_NFKB-0.310
- ANGIOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.877 |
| 2 | TCGA-75-5147-01A-01R-1628-07 | — | cohortA1 | 0.875 |
| 3 | MDT-AP-2288 | Med | Medulloblastoma | 0.859 |
| 4 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.817 |
| 5 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.814 |
| 6 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.814 |
| 7 | 45a2676b-25ba-41b0-9e55-08c6eb3a8f2f | — | — | 0.814 |
| 8 | TCGA-37-4130-01A-01R-1100-07 | — | cohortA1 | 0.804 |
| 9 | MNG85 | — | — | 0.799 |
| 10 | SRR1313162 | — | C | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |